Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
29.2 DKK | -5.19% | -3.95% | +6.38% |
Apr. 23 | Transcript : Embla Medical hf., Q1 2024 Earnings Call, Apr 23, 2024 | |
Apr. 23 | Embla Medical hf. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Sales forecast by analysts have been recently revised upwards.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The group shows a rather high level of debt in proportion to its EBITDA.
- The company benefits from high valuations in earnings multiples.
- The company is highly valued given the cash flows generated by its activity.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+6.38% | 1.88B | B+ | ||
-0.41% | 23.92B | B | ||
-8.42% | 16.65B | A | ||
+7.14% | 13.6B | B | ||
+7.09% | 10.01B | B- | ||
-19.75% | 2.01B | - | ||
+34.39% | 1.67B | D- | ||
0.00% | 492M | - | - | |
+31.01% | 139M | - | ||
+27.93% | 104M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- EMBLA Stock
- Ratings Embla Medical hf.